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Abstract
The gene of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4), a negative regulator of T lymphocytes, contains a single-
nucleotide polymorphism (SNP) at position +6230A-.G (ct60A-.G), which has been found associated with several
autoimmune diseases and appears to reduce T-cell inhibitory activity. In Ghana, West Africa, we compared the frequencies
of CTLA4 +6230 A/G and 6 haplotype-tagging SNPs in 2010 smear-positive, HIV-negative patients with pulmonary
tuberculosis (TB) and 2346 controls matched for age, gender and ethnicity. We found no difference in allele frequencies
between cases and controls. However, +6230A and a distinct CTLA4 haplotype and a diplotype comprising the +6230A allele
were significantly less frequent among cases with large opacities in chest radiographs compared to those with small ones
(Pcorrected [cor]=0.002, Pcor=0.00045, P=0.0005, respectively). This finding suggests that an increased T-cell activity
associated with the CTLA4 +6230G allele contributes to pathology rather than to protection in pulmonary TB.
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Introduction
Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) is
considered a key negative regulator of T lymphocytes [1]. Being
transiently surface expressed and released by activated T cells, it
inhibits T-cell functions through a variety of direct and indirect
mechanisms [2–7]. In addition, CTLA-4 has been found to skew
the activity of T-helper (Th) cells towards a Th1 phenotype [8–9].
AG RA nucleotide exchange at position +6230 (also addressed
as CT60; according to alternate numbering located at position
+6253 relative to the start codon) in the 39-untranslated region of
the human CTLA-4 gene has been found to support protection
from several autoimmune diseases [10]. It was associated with an
increased concentration of a splice variant of the CTLA4 transcript
encoding a soluble form of the molecule, which was assumed to
enhance the T-cell inhibitory function [10,11]. The authors
reasoned that the autoimmunity-supporting +6230G allele of
CTLA4, which was found in the majority of members of the
European study group, may have been the subject of evolutionary
selection by providing enhanced cellular immune responses and,
thereby, protection against particular intracellular infections [10].
The identification of this polymorphism provided an important
tool to study the overall influence of T-cell responses in humans.
We studied the CTLA4 +6230 polymorphism in pulmonary
tuberculosis (TB) for two reasons. First, T cells are regarded of
eminent importance in controlling mycobacterial infections [12].
In addition, TB may be relevant in the evolution of the
autoimmunity-associated +6230G allele because it is caused by
an intracellular infection and, due to its widespread occurrence
and high mortality in the past and today, it may be relevant to
natural selection.
Studying an African population, we included in the analysis four
single nucleotide polymorphisms (SNP) which recently have been
described to characterize the relevant haplotypes of the CTLA4
gene in Africans [13] and, according to the most recent version of
the HapMap database (http://www.hapmap.org/) five additional
tagging SNPs providing comprehensive and appropriate coverage
of the CTLA4 gene.
Materials and Methods
Study group
Study participants were enrolled in Ghana, West Africa,
between September 2001 and July 2004. The study group has
been described in detail elsewhere [14]. In brief, patients were
recruited at the two major teaching hospitals of Accra and
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Obuasi, Agona, Mampong, Agogo, Konongo, Nkawie, Nkawkaw,
Atibie, Assin Fosu and Dunkwa. The characterization of patients
comprised a documentation of medical histories on standardized
questionnaires, two examinations for acid-fast bacilli of non-
induced sputum specimens, a determination of HIV serology and
confirmation of positive results by an alternative test, culturing and
differentiation of mycobacterial isolates by IS6110 fingerprinting
and spoligotyping as well as assessment of drug resistances, and a
posterior-anterior chest radiography.
Included were patients 6 to 60 years of age, with no history of
previous TB or anti-mycobacterial treatments, two sputum smears
positive for acid-fast bacilli, and a negative HIV serology.
Excluded were individuals with incomplete information provided
by the questionnaire or evidence for alcoholism, drug addiction or
other apparent generalized disease.
Unrelated personal contacts and neighbours as well as commu-
nity members were recruited as controls. Inclusion criteria were no
history of previous TB or anti-mycobacterial treatments and no
evidenceforpreviousTBinchestradiographs.The characterization
of controls included a tuberculin skin test (Tuberculin Test PPD
Me ´rieux, bioMe ´rieux, Nu ¨rtingen, Germany).
Radiographic films were pseudonymized and read by an
experienced radiologist (G. S.). Opacities, cavities, nodular lesions,
pulmonary shrinkage (loss of lung volume as assessed by hilus
dislocation or displacement of fissures), calcifications, and pleural
thickening were individually assigned to the upper right, lower right,
upper left, and lower left thoracic quadrants and overall assessed
quantitatively being rated ‘‘0’’ (no lesion detectable), ‘‘1’’ (mild
lesion), ‘‘2’’ (moderate lesion), and ‘‘3’’ (severe lesion). Enlargements
of mediastinal lymph nodes, effusions, and miliary lesions were
evaluated qualitatively. The evaluation presented here for the
reason of simplicity was restricted to the overall scores for opacities
and cavities because these are the most common signs of TB
reflecting cellular infiltration and necrosis, respectively (Table 1).
The final study group comprised 2010 cases and 2346 controls
comprising 1211 household contacts and 1135 neighbours or
community controls. They belonged to the following ethnic groups
(cases/all controls/PPD-positive controls/PPD-negative controls):
Akan including Ashanti, Fante, Akuapem (63.6%/59.1%/58.2%/
74.8%), Ga-Adangbe (14.5%/19.8%/20.6%/7.0%), Ewe (7.1%/
9.3%/9.6%/3.9%) and ethnic groups of northern Ghana,
including Mole Dagbane, Gurma, Grusi (12.9%/10.4%/10.3%/
12.6%). For 1.6% of study participants the ethnicity was not
clearly assignable. The percentage of males among cases, all
controls, PPD-positive controls and PPD-negative controls was
68.2%/59.2%/60.2%/42.5%, respectively. The mean age of
study participants in these groups was 34.1611.6/32.5612.0/
32.4611.8/34.1615.3.
The study protocol was approved by the Committee on Human
Research, Publications and Ethics, School of Medical Sciences,
Kwame Nkrumah University, Kumasi, and the Ethics Committee
Table 2. Primers and sensor/anchor oligonucleotides used for CTLA4 genotyping
1.
CTLA4 SNP rs Number Primer Oligonucleotides
2 Sensor/Anchor Oligonucleotides
3
21765 A/G rs11571315 F–CTGCTAAGAGCATCCGC S–TCAACTCCAGCATTGATCTCACTCTAT
R–TGTTGGTGTGATGCACAG A–GCTGAACCACTGGCTTCTGCTCCTCTACATAATAC
21722 A/G rs733618 F–CTGCTAAGAGCATCCGC S–GGGTTTAGCTGCCTGTCCC
R–TGTTGGTGTGATGCACAG A-GCCACTGCTGTGTGTTCCTCTTGAGG
21661 A/G rs4553808 F–CTGCTAAGAGCATCCGC S–TGGGCAACAGAGGTTTTTCAAAAAG
R–TGTTGGTGTGATGCACAG A–CAATAACAACCTAATGGGCACTTCCTAATGCCAGA
21577 C/T rs11571316 F–CTGCTAAGAGCATCCGC S–CTGGGGCTTGAAGGTTTCTATAATGTGTA
R–TGTTGGTGTGATGCACAG A–CAGTGTATAGAAAACAGGCAGGTCAGAAAAGGC
21147 C/T rs16840252 F_AGGGAGGCATTTGGTGA S_GGACGGACTGGAGTAGGCAA
R_CCGGAATTCTGTGCACTT A_GTCATATTCCCTGTTACAACTGTCTGTTTGCATGT
2443 A/T rs231774 F_AGAAGGATGGTGCTTCACA S_GCCTAGTAGTTTTGGAGATGTCAATGAAATGA
R_TGGAGAATTTCCTGGAGTACA A_TGGACTGGATGGTTAAGGATGCCCAGAAG
+49 G/A rs231775 F–TGCCTTGGATTTCAGCG S–CCAGGTCCTGGCAGCC
R–TGAAACAAATGAAACCCAGGTAG A–AGGGATGAAGAGAAGAAAAAACAGGAGAGTGCAG
+923 C/T rs231777 F_TGTGGGTTTCAGATGCAG S_TGGCTAAGAAACCATGTAGTTTGTATGAAGTAG
R_CTTTCCAGTATTGGGAGGG A_CCATTGAATCTCAACCTTATCTCTCTCTAGACCTT
+6230 G/A rs3087243 F–TTCATTCAGTATCTGGTGGAGTCTC S–GGGATATAACATGGGTTAACACAG
R–AAGGGGAGGTGAAGAACCTG A–CATAGCAGTCCTTTATAAATCAATTGGCA
1Performed by dynamic allele specific hybridisation with fluorescence resonance energy transfer (FRET) in a LightTyper.
2F, forward primer; R, reverse primer.
3S, sensor; A, anch.
doi:10.1371/journal.pone.0006307.t002
Table 1. Radiographic findings in the case group
1.
Severity score Opacities Cavities
0 17 (0.9%) 103 (5.6%)
1 340 (18.4%) 825 (44.6%)
2 1121 (60.6%) 682 (36.8%)
3 373 (20.2%) 241 (13.0%)
1Shown are numbers of patients and, in brackets, percentages of total
(n=1851).
doi:10.1371/journal.pone.0006307.t001
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according to the ’’Directly Observed Treatment, Short-course’’
(DOTS) strategy organized by the National Tuberculosis Pro-
gramme. Blood samples for genetic analyses and HIV testing were
taken only after a detailed explanation of the study aims and
written or thumb-printed consent for participation provided,
including HIV testing. Disclosure of HIV test results was
dependent on the documented willingness of participants to be
informed. HIV-positive patients were promptly referred to
counseling and treatment as provided by the Ghanaian AIDS
Control Programme.
Genetic Analysis
After DNA extraction from whole peripheral blood by a
magnetic separation technology (AGOWAH, Berlin, Germany),
the CTLA4 21765 (rs11571315), 21722 (rs733618), 21661
(rs4553808), 21577 (rs11571316), 21411 (rs16840252), 2443
(rs231774), +49 (rs231775), +923 (rs231777) and +6230
(rs3087243) variants were analysed by dynamic allele specific
hybridization with fluorescence resonance energy transfer (FRET)
in a LightTyper (Roche Diagnostics, Mannheim, Germany).
Primer pair and sensor/anchor oligonucleotides for LightTyper-
based genotyping are listed in Table 2.
Statistical Analysis
The STATA 9 software (Stata Corporation, College Station,
TX, USA) was used to test for Hardy Weinberg equilibria (HWE)
and odds ratios (OR) of genotype frequencies. Multivariate logistic
regression analyses were applied to adjust for age, gender and
ethnicities when comparing TB cases with all controls, PPD-
negative and PPD-positive controls. Multivariate ordinal logistic
regression analyses were performed to determine the influences of
genetic variants on the severity scores of radiological signs.
Calculations included adjustments for age, gender, ethnicity,
recruitment centers and duration of cough, the latter because it
was found correlated with the radiographic signs. Haplotype
Table 3. Frequencies and distributions of SNPs studied
1.
Genetic Variant MAF
2 Cases Controls
P
3 P
3
CTLA4 21765 0.46 0.54 0.40
CTLA4 21722 0.15 0.81 0.04
CTLA4 21661 0.16 0.49 0.51
CTLA4 21577 0.19 0.82 0.47
CTLA4 21147 0.16 0.82 0.57
CTLA4 2443 0.17 0.73 0.53
CTLA4 +49 0.38 0.62 0.65
CTLA4 +923 0.25 0.73 0.09
CTLA4 +6230 0.19 0.99 0.64
1The x2 test was applied to test for deviations from Hardy-Weinberg
equilibrium.
2Minor allele frequency.
3P value for a deviation from Hardy-Weinberg equilibrium.
doi:10.1371/journal.pone.0006307.t003
Figure 1. Pairwise linkage disequilibrium (r
2) based on 9 CTLA4 SNPs using HaploView 4.0 software. The figure depicts the strong LD of
variants 21577/+6230 and of variants 21147/21661. The positions relative to the ATG start codon of SNPs are given in Table 2.
doi:10.1371/journal.pone.0006307.g001
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module of the haplo.stats package (http://cran.r-project.org/web/
packages/haplo.stats/index.html).
Associations of the distinct disease phenotypes of opacities and
cavities with CTLA4 diplotypes comprising the +6230A allele were
determined by weighted ordinal logistic regression analyses.
Weights in the regression models were the posterior probabilities
of each haplotype pair (diplotype) for each individual as estimated
by the haplo.score module of the haplo.stats package.
Corrections for multiple testing of single variants were made by
multiplication of P values with 7, the number of genetic variants
that are not in strong linkage disequilibria with each other, and the
two disease phenotypes examined. The final correction factor was,
thus, 14 and corrected P values are given as Pcor. To control
haplotype analyses for multiple testing, 20,000 permutations were
performed for global and haplotype-specific P values. The study
sample provided 80% power to identify significant genotypic
differences between TB cases and controls at a statistical support
level of a=10
24 with an OR of 1.4 and a minor allele frequency
of 0.1 applying a multiplicative model.
Results
The study group consisted of 2010 patients with pulmonary TB
and 2346 controls group-matched for age, gender and ethnicity.
Controls comprised 2219 purified protein derivative (PPD)-
positive and 127 PPD-negative individuals
Genotyping of 8 SNPs located in the CTLA4 gene showed allele
distributions in HWE in both the patient and control groups. The
minor allele frequencies (MAF) of variants was 15–46%, whereby
the +6230 (ct60) A and G alleles were found in 19% and 81%,
respectively, of participants. CTLA4 21722 showed a minor
deviation from HWE in the control group but as this occurred in
one subgroup only it was considered fortuitous (Table 3).
Table 4. CTLA4 genotype frequencies in TB cases and
controls
1.
CTLA4 SNP Cases Controls OR
3 95%CI
4 p
N 1990 2337
21765 AA 29.1% 29.1% 1
AG 49.0% 50.5% 0.97 0.8–1.1 0.623
GG 21.8% 20.4% 1.04 0.9–1.2 0.639
N 1986 2315
21722 AA 72.9% 70.2% 1
AG 24.9% 27.9% 0.88 0.8–1.0 0.067
GG 2.2% 1.9% 1.18 0.8–1.8 0.435
N 1952 2269
21661 AA 71.6% 70.6% 1
AG 25.8% 26.6% 0.94 0.8–1.1 0.364
GG 2.6% 2.8% 0.89 0.6–1.3 0.552
N 934 1057
2443 AA 68.8% 68.0% 1
AT 28.1% 28.6% 0.98 0.8–1.2 0.852
TT 3.1% 3.4% 0.90 0.5–1.5 0.680
N 1912 2278
+49 GG 40.1% 38.7% 1
GA 46.0% 47.4% 0.95 0.8–1.1 0.456
AA 13.9% 13.9% 0.98 0.8–1.2 0.826
N 903 1026
+923 CC 54.7% 57.7% 1
CT 38.2% 35.2% 1.15 1.0–1.4 0.146
TT 7.1% 7.1% 1.07 0.7–1.5 0.724
N 1994 2328
+6230 GG 64.6% 65.7% 1
GA 31.5% 30.5% 1.05 0.9–1.2 0.494
AA 3.9% 3.8% 1.04 0.8–1.4 0.822
1Analysed by logistic regression.
2Variations due to assay failures.
3Odds ratio.
4Confidence interval.
doi:10.1371/journal.pone.0006307.t004
Table 5. CTLA4 genotype frequencies in TB cases stratified for
the sizes of opacities in chest radiographs
1.
Opacity Score
CTLA4 SNP 0 1 2 3 OR
2 95%CI
3 PP cor
4
N 17 349 1075 364
21765 AA 0.0% 30.1% 29.6% 26.4% 1
AG 64.7% 44.7% 49.3% 51.4% 1.09 0.9–1.4 0.498
GG 35.3% 25.2% 21.1% 22.2% 0.85 0.6–1.1 0.268
N 17 347 1074 363
21722 AA 82.3% 74.3% 72.6% 71.1% 1
AG 17.6% 23.1% 24.9% 27.3% 1.14 0.9–1.5 0.277
GG 0.0% 2.6% 2.4% 1.6% 1.09 0.5–2.3 0.822
N 17 342 1056 357
21661 AA 52.9% 73.1% 71.9% 68.9% 1
AG 47.1% 24.0% 25.9% 27.4% 1.05 0.8–1.3 0.692
GG 0.0% 2.9% 2.3% 3.6% 1.25 0.6–2.4 0.505
N 3 183 565 183
2443 AA 100.0% 68.3% 69.2% 67.8% 1
AT 0.0% 29.0% 27.1% 30.6% 1.03 0.8–1.4 0.838
TT 0.0% 2.7% 3.7% 1.6% 0.83 0.4–1.7 0.618
N 17 338 1040 347
+49 GG 52.9% 45.9% 37.7% 40.6% 1
GA 47.1% 42.6% 47.9% 46.1% 1.17 0.9–1.5 0.180
GG 0.0% 11.5% 14.4% 13.3% 1.38 1.0–1.9 0.061
N 3 180 545 175
+923 CC 66.7% 51.7% 55.2% 56.0% 1
CT 33.3% 41.1% 38.6% 34.3% 0.84 0.7–2.3 0.289
TT 0.0% 7.2% 6.2% 9.7% 1.33 0.6–1.1 0.199
N 17 350 1079 364
+6230 GG 47.1% 63.1% 65.6% 63.2% 1
GA 47.1% 29.4% 30.8% 35.2% 1.06 0.8–1.3 0.602
AA 5.9% 7.4% 3.6% 1.6% 0.39 0.2–0.7 0.0004 0.005
1Analysed by ordinal logistic regression.
2Odds ratio.
3Confidence interval.
4Bonferroni-corrected by the factor of 14 for testing 7 SNPs not in strong
linkage disequilibria and two disease phenotypes.
doi:10.1371/journal.pone.0006307.t005
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strong LDs between the variants 21577 with +6230 (R
2=0.94)
and 21147 with 21661 (R
2=0.96) (Figure 1). Due to these LDs,
the SNPs at positions 21577 and 21147 could safely be excluded
from further analyses as these variants would not add additional
information.
When comparing cases with controls, genotype frequencies were
similar in all groups (Table 4) including subgroups of PPD-positive
and PPD-negative controls (data not shown). Associations with
disease severity were assessed by multivariate ordinal logistic
regression based on quantitative estimates of radiographic signs of
opacities and cavities. Age, gender, ethnicity, duration of illness,
mycobacterial species (M. tuberculosis 69.1%, M. africanum 30.3%, M.
bovis 0.6%), and recruitment site were included as potentially relevant
co-variates. The stratifications showed that the A/A genotype of
+6230 showed a significant association with low scores for opacities
(Table 5) and a similar trend for cavities (data not shown). Compared
to the most frequent +6230 G/G genotype, the A/A and A/G
genotypes had odds ratios (ORs) of 0.39 (AA vs GG, confidence
interval [CI] 0.23–0.65, Pcor=0.005) and 1.06 (AG vs GG, CI 0.85–
1.33, ns), respectively. As no difference was found between A/G and
G/G and both genotypes showed similar ORs compared to A/A
(GG vs AA, OR 2.57, CI 1.53–4.32, Pcor=0.005 and AG vs AA, OR
2.72, CI 1.60–4.66, Pcor=0.003), the disease-aggravating influence
associated with the G allele appears to be dominant and the disease-
mitigating effect associated with A recessive.
The haplotype 21765G/21722A/21661A/2443A/+49 G/
+923C/+6230A was strongly associated with high opacity scores
in a recessive model (global Pcor=0.03; haplotype specific
Pcor=0.0005) and showed the same, albeit weaker, association
with cavities (global Pcor=0.03; haplotype specific Pcor=0.03)
(Table 6). The same applied to the diplotype containing
homozygously this haplotype (opacities: haplotype specific
P=0.0005; cavities: haplotype specific P=0.05; Table 7).
Discussion
Our findings do not provide evidence for a role of the +6230
polymorphism of human CTLA4 in protection against pulmonary
TB. On the other hand, our study design was sufficiently sensitive
to detect a significant influence of the +6230 variant on the more
detailed phenotypes of disease severity as radiograpically assessed
by the extent of opacities and size and numbers of pulmonary
cavities. The +6230 A/A genotype, which had been found
negatively associated with autoimmune disease, was found to also
be negatively associated with severe pathology in pulmonary TB.
This applied to the major forms of pathology as identified by chest
X ray. Thus, the CTLA4 +6230 polymorphism was found to
influence pulmonary TB only after Mycobacterium tuberculosis had
overcome innate and adaptive host defence mechanisms.
Our data are partly supported by earlier studies in a murine
model of TB. Using experimental aerosol infection of mice with
Mycobacterium bovis bacillus Calmette-Gue ´rin (BCG), it was shown
that inhibition of CTLA-4 by antibody did not enhance protection
[15]. Furthermore, in the same model, depletion of regulatory T
cells, which express CTLA-4 constitutively, did not affect protection
either [16]. However, the mouse model did not support a role of
CTLA-4 in enhancing pathology. Although antibody mediated
inhibition of CTLA-4 caused a rise in the number of T cells in lung-
draining lymph nodes and an increase in the T-cell proliferative
Table 6. CTLA4 haplotype frequencies in TB cases stratified for the sizes of opacities and cavities in chest radiographs
1.
CTLA4 SNP
Haplotypes 21765 21722 21661 2443 +49 +923 +6230 Freq.
4 Score statistic
5 P
6 Pcor
7
Opacities Global p=0.02
2, Global pcor=0.03
3
G A A A G C A 0.19 23.70 0.00021 0.00045
A A A T G C G 0.08 21.05 0.29 0.30
A G A A A C G 0.15 20.60 0.55 0.55
A A A T G T G 0.06 20.29 0.77 0.77
G A G A G T G 0.13 0.39 0.69 0.70
A A A A A C G 0.21 0.66 0.51 0.52
G A A A G C G 0.11 0.68 0.50 0.50
Cavities Global p=0.005
2, Global pcor=0.008
3
A A A T G C G 0.08 22.19 0.03 0.03
G A A A G C A 0.19 22.11 0.04 0.03
G A G A G T G 0.13 21.6 0.11 0.11
G A A A G C G 0.11 21.61 0.11 0.11
A G A A A C G 0.15 21.05 0.29 0.29
A A A T G T G 0.06 0.15 0.88 0.88
A A A A A C G 0.21 2.08 0.04 0.04
1Seven tagging SNPs reported to appropriately indicate CTLA4 haplotypes in sub-Saharan Africans (Ref. 13) analysed by the Haplo.score software assuming a recessive
mode of inheritance.
2P values obtained testing an overall association between haplotypes and the phenotype.
3Global P values corrected for multiple testing by 20,000 permutations.
4Frequency; only haplotypes with a frequency.0.01 are shown.
5P values of haplotype-specific associations.
6Simulated haplotype-specific P values corrected for multiple testing by 20,000 permutations.
7Score statistic of the haplo.score software.
doi:10.1371/journal.pone.0006307.t006
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lymphoid infiltration or granuloma formation in the lung assessed
by careful histological examination [15]. As theradiological findings
of opacities and cavities in human TB are considered to result from
cellular infiltration and necrosis, respectively [17], our observations
suggest that, in humans, a reduced activity of CTLA-4 causes an
increased cellular infiltration of the lung, which may result from in-
situ T-cell proliferation and recruitment of other cell types through
cytokines. This is in agreement with the concept that pathology of
TB to some extent is immune mediated, which has recently been
confirmed by finding a clinical aggravation of pre-existing TB in the
course of the immune reconstitution inflammatory syndrome (IRIS)
seen among AIDS patients undergoing anti-retroviral therapy [18].
Collectively, the observation of the role of the CTLA4 26230
polymorphism and the occurrence of a haplotype/diplotype bearing
the CTLA4A variant in pulmonary TB indicates that a reduced
CTLA-4 activity in humans does not enhance protection against
pulmonary TB but enhances pathology if containment of the
infection fails. Accordingly, pulmonary TB appears not to belong to
those infections which may contribute to explain the high prevalence
of CTLA4+6230G in human populations. Thisevolutionaryrolemay
rather be with viral infections including hepatitis B, which was found
to be controlled more effectively by carriers of the CTLA4 +6230G
allele than by those carrying the +6230A/A genotype [19]. In that
study, the +6230G allele appeared to act in a dominant fashion,
w h i c hi si na g r e e m e n tw i t ht h er e s u l t so b t a i n e di na u t o i m m u n i t y[ 2 0 ]
but at variance with our data on the severity of TB. An explanation
has to await further functional studies.
The higher frequency of +6230G allele in the Ghanaian study
group (.80%) compared to that found in Europeans (,60%) may
suggest an evolutionary influence exerted by diseases that occur at
higher prevalences in Africa than in Europe.
Our finding of strong LD in a study population from West
Africa between variants at position +6230 and the SNP located in
the promoter region of CTLA4 (21577) may open new avenues in
the search for mechanisms which mediate the immunomodulatory
effect of the +6230 variant.
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Table 7. CTLA4 diplotype analysis in TB cases stratified for the
sizes of opacities and cavities in chest radiographs.
Diplotype Opacity Score
0123O R
1 95% CI
2 P
5
N 17 305 961 331
Other
3/other 47.1% 60.3% 62.8% 61.3% 1
HAPct60
4/other 47.0% 31.8% 33.2% 36.9% 1.03 0.8–1.3 0.826
HAPct60/HAPct60 5.9% 7.9% 4.0% 1.8% 0.39 0.2–0.7 0.0005
Cavity Score
N 17 305 961 331
Other/other 64.0% 60.9% 63.4% 60.4% 1
HAPct60/other 31.0% 33.7% 33.2% 37.2% 1.03 0.8–1.3 0.77
HAPct60/HAPct60 5.0% 5.4% 3.4% 2.4% 0.59 0.3–1.0 0.05
1Odds ratios (OR).
295% confidence intervals (CI) for the weighted ordinal logistic regression
model with weights being the posterior probabilities for each diplotype for
each individual.
3Other, haplotype not comprising the +6230A allele.
4HAPct60, haplotype comprising the +6230A allele (21765 G/21722 A/21661
A/2443 A/+49 G/+923 C/+6230 A).
5P values given for haplotype-specific associations.
doi:10.1371/journal.pone.0006307.t007
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